We observed that melanoma patients with FASN mutations exhibited a significantly decreased FASN expression (Wilcoxon rank-sum test, p = 0.006; Figure S9A), which is consistent with the evidence that patients with low FASN expression responded better to ICI treatments. The gene discussed is FASN; the disease is melanoma.